If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksJames Halstead Regulatory News (JHD)

Share Price Information for James Halstead (JHD)

Share Price is delayed by 15 minutes
Get Live Data
129.00    1.00 (0.78%)
Bid:
128.40
Ask:
129.00
Spread: 0.60 (0.467%)
Market Cap: £537.17m
JHD Live PriceLast checked at - London Stock Exchange

Intraday James Halstead Share Chart

Trading Update

29 Jul 2025 07:00

RNS Number : 8873S
James Halstead PLC
29 July 2025
 

 

29 July 2025

 

 

JAMES HALSTEAD PLC (the "Company")

 

Trading Update

James Halstead plc, the commercial flooring manufacturer and international distributor, is providing the following trading update ahead of its results for the year ended 30 June 2025.

 

The Company sells, for the most part, commercial flooring across the world and has seen continued confidence in the segment of resilient sheet flooring but has experienced headwinds against sales of luxury vinyl tile (LVT) principally in Europe, the Company has however successfully managed to grow its market share in the UK. Profit before tax is in line with expectations.

 

Sales in the UK, our largest market, have improved compared to the prior financial year. Having reported that in the prior financial year there was a 5% decline versus the comparative, it is pleasing to note that our performance this year has seen this decline more than fully reverse. This is despite a degree of de-stocking by some customers, particularly those with exposure to the UK domestic carpet market.

 

Sales volumes of LVT have increased, albeit modestly, in a market segment that has seen a large decline in demand. Sales of Polyflor branded LVT products have held up due to their quality and value together with our widely accepted reputation for sustainability and environmental excellence; factors that have helped increase our market share. LVT and sheet vinyl continue to displace carpet sales in the UK market.

 

Notwithstanding this backdrop and solid UK performance, our internal expectations for the UK were higher. An anticipated uplift in demand in the education, healthcare and the prison sectors has not, yet, materialised though sales into the aged care and affordable housing sectors are performing satisfactorily.

 

In Europe, particularly in France and Holland, there has been muted activity in consumer spending which has affected refurbishment demand and new store openings in the retail sector. This has impacted LVT sales and volume declines were further compounded by increased focus of government budgets towards national security, diverting spending away from such areas as construction and social housing.

 

The products we sell are still regarded as market leading but the year has required reacting to a lower level of sales by tight cost control. In this regard, the simple model of holding stock within our distribution chain to supply demand is tried and tested around the globe.

 

In our Rest of World markets, sales have generally been more positive with very good growth, especially in the Americas, the Middle East and Mediterranean regions. Additionally, South Asia has seen the growth of recent years continue and is 38% ahead of the comparative of last year.

 

Notwithstanding the slower sales, the Group's focus on manufacturing efficiency and tight cost control of overheads have protected margins.

 

Operationally, there has been disruption to global trade routes and shipping movements with the uncertainty of tariffs on sales into the USA which has affected deliveries into many markets. However, these uncertainties have been positive regarding the sale of our UK manufactured goods into the USA, as customers seek alternative suppliers to replace products imported from countries where much higher tariffs have been imposed and with continuing uncertainly. This increased demand is despite an additional 10% duty cost to importers of our UK products.

 

In summary, the Company anticipates that sales will be marginally below the 2024 comparative with profit slightly below last year's record levels; although remaining within the range of market expectations. Cash generation alongside reserves continue to underpin an ungeared balance sheet, which remains strong.

 

The Board is confident that the prospects remain solid despite the recent external challenges and side winds.

 

The Company expects to announce its results for the year ended 30 June 2025 towards the end of September 2025.

 

 

 

 

 

Enquiries:

 

James Halstead plc

Tel: 0161 767 2500

Mark Halstead, Executive Chairman

Gordon Oliver, Chief Executive

David Drillingcourt, Finance Director

 

Hudson Sandler

Tel: 020 7796 4133

Nick Lyon / Nick Moore

Panmure Liberum (Nomad and Joint Broker)

Tel: 020 7886 2500

Ed Mansfield / Tom Scrivens

Zeus (Joint Broker)

Ben Thorne / Fraser Marshall

 

Tel: 020 3829 5000

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTPKFBQCBKDPOB
Date   Source Headline
6th Dec 20194:35 pmRNSResult of AGM
6th Dec 20198:30 amRNSAGM Statement
18th Oct 20199:51 amRNSNotice of Results
1st Oct 20197:00 amRNSPreliminary Results
18th Sep 20197:00 amRNSNotice of Preliminary Results
23rd Aug 20194:37 pmRNSPrice Monitoring Extension
30th Jul 20197:00 amRNSPre-Close Trading Statement
3rd Jul 20194:41 pmRNSNew Corporate Website
3rd Jun 201910:31 amRNSTotal Voting Rights
15th May 20198:08 amRNSDirector/PDMR Shareholding
10th May 20192:36 pmRNSDirector/PDMR Shareholding
3rd May 20192:07 pmRNSTotal Voting Rights
2nd Apr 20199:57 amRNSBlock listing Interim Review
1st Apr 20196:19 pmRNSTotal Voting Rights
29th Mar 20197:00 amRNSInterim Results
28th Mar 20191:24 pmRNSNotice of Interim Results - Update
25th Mar 20199:35 amRNSNotice of Interim Results
30th Jan 20197:00 amRNSPre Close Trading Statement
28th Jan 20191:16 pmRNSDirector/PDMR Shareholding
7th Dec 20184:13 pmRNSResult of AGM
7th Dec 20187:00 amRNSAGM Statement
19th Oct 20184:02 pmRNSAnnual Financial Report and Notice of AGM
19th Oct 20187:00 amRNSDirector/PDMR Shareholding
18th Oct 20187:00 amRNSAdditional Listing
18th Oct 20187:00 amRNSTotal Voting Rights
16th Oct 20186:13 pmRNSBlock listing Interim Review
27th Sep 20184:48 pmRNSDirector/PDMR Shareholding
26th Sep 20187:00 amRNSPreliminary Results
17th Sep 20187:00 amRNSNotice of Preliminary Results
25th Jul 20187:00 amRNSPre-Close Trading Statement
22nd May 20184:58 pmRNSRule 2.8 Announcement
22nd May 20189:39 amRNSForm 8.5 (EPT/RI) - James Halstead PLC
21st May 20189:46 amRNSForm 8.3 - James Halstead
18th May 20182:52 pmRNSForm 8.3 - James Halstead
18th May 201811:50 amRNSForm 8.5 (EPT/NON-RI)
17th May 201811:50 amRNSForm 8.5 (EPT/NON-RI)
17th May 20187:57 amRNSForm 8.5 (EPT/RI) - James Halstead PLC
16th May 201811:50 amRNSForm 8.5 (EPT/NON-RI)
15th May 201811:50 amRNSForm 8.5 (EPT/NON-RI)
14th May 201811:57 amRNSForm 8.5 (EPT/NON-RI)
11th May 20183:26 pmRNSDirector/PDMR Shareholding
11th May 201811:50 amRNSForm 8.5 (EPT/NON-RI)
11th May 201810:20 amRNSForm 8.3 - James Halstead
11th May 20189:07 amRNSForm 8.5 (EPT/RI) - James Halstead PLC
10th May 20181:36 pmRNSDirector/PDMR Shareholding
10th May 201811:50 amRNSForm 8.5 (EPT/NON-RI)
10th May 20189:12 amRNSForm 8.3 - James Halstead
9th May 20183:29 pmBUSForm 8.3 - James Halstead PLC
9th May 201811:57 amRNSForm 8.5 (EPT/RI) - James Halstead PLC
9th May 201811:57 amRNSForm 8.5 (EPT/NON-RI)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.